Cancers and erectile dysfunction: a Mendelian randomization study.

IF 3.9 2区医学 Q2 ENDOCRINOLOGY & METABOLISM Frontiers in Endocrinology Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI:10.3389/fendo.2024.1417830

Ge Yang, Yuanguo Xiong, Ziwen Wang, Jingsong Wang, Yongchuan Chen, Hong Zhang

{"title":"Cancers and erectile dysfunction: a Mendelian randomization study.","authors":"Ge Yang, Yuanguo Xiong, Ziwen Wang, Jingsong Wang, Yongchuan Chen, Hong Zhang","doi":"10.3389/fendo.2024.1417830","DOIUrl":null,"url":null,"abstract":"Purpose: Cancer often coexists with erectile dysfunction, yet the causal relationship between them remains unclear. This study aims to investigate the causal link between tumors and ED through Mendelian randomization.Method: Data on 13 different cancers, including lung cancer, colorectal cancer, testicular cancer, lymphoma, esophageal cancer, pancreatic cancer, thyroid cancer, bladder cancer and brain cancer were collected from various databases. ED data, comprising 2,205 cases and 164,104 controls, were sourced from the FinnGen project. Primary methods for MR analysis included IVW, MR-Egger, weighted median, and weighted mode.Results: IVW results revealed associations between colorectal cancer (OR=1.17;95% CI 1.02-1.13, p=0.0252), prostate cancer (OR=1.63;95% CI 1.52-1.75, p<0.001) and liver cancer (OR=0.93;95% CI 0.88 -0.99, p=0.012) with ED.Conclusion: Mendelian randomization analysis supports that prostate cancer and colorectal cancer are associated with an increased risk of Erectile Dysfunction, whereas liver cancer is linked to a decreased risk of ED. No evidence suggests that ED contributes to an increased risk of prostate cancer.","PeriodicalId":12447,"journal":{"name":"Frontiers in Endocrinology","volume":"15 ","pages":"1417830"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578273/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fendo.2024.1417830","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Cancer often coexists with erectile dysfunction, yet the causal relationship between them remains unclear. This study aims to investigate the causal link between tumors and ED through Mendelian randomization.

Method: Data on 13 different cancers, including lung cancer, colorectal cancer, testicular cancer, lymphoma, esophageal cancer, pancreatic cancer, thyroid cancer, bladder cancer and brain cancer were collected from various databases. ED data, comprising 2,205 cases and 164,104 controls, were sourced from the FinnGen project. Primary methods for MR analysis included IVW, MR-Egger, weighted median, and weighted mode.

Results: IVW results revealed associations between colorectal cancer (OR=1.17;95% CI 1.02-1.13, p=0.0252), prostate cancer (OR=1.63;95% CI 1.52-1.75, p<0.001) and liver cancer (OR=0.93;95% CI 0.88 -0.99, p=0.012) with ED.

Conclusion: Mendelian randomization analysis supports that prostate cancer and colorectal cancer are associated with an increased risk of Erectile Dysfunction, whereas liver cancer is linked to a decreased risk of ED. No evidence suggests that ED contributes to an increased risk of prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症与勃起功能障碍：孟德尔随机研究。

目的：癌症常常与勃起功能障碍并存，但两者之间的因果关系仍不清楚。本研究旨在通过孟德尔随机法研究肿瘤与勃起功能障碍之间的因果关系：方法：从各种数据库中收集 13 种不同癌症的数据，包括肺癌、结直肠癌、睾丸癌、淋巴瘤、食管癌、胰腺癌、甲状腺癌、膀胱癌和脑癌。ED 数据来自 FinnGen 项目，包括 2,205 例病例和 164,104 例对照。MR分析的主要方法包括IVW、MR-Egger、加权中位数和加权模式：IVW结果显示结肠直肠癌（OR=1.17；95% CI 1.02-1.13，p=0.0252）、前列腺癌（OR=1.63；95% CI 1.52-1.75，pConclusion）之间存在关联：孟德尔随机分析证实，前列腺癌和结肠直肠癌与勃起功能障碍风险增加有关，而肝癌则与勃起功能障碍风险降低有关。没有证据表明勃起功能障碍会导致前列腺癌风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

5.70

自引率

9.60%

发文量

3023

审稿时长

14 weeks

期刊介绍： Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.

期刊最新文献

Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study. Mitochondria: the epigenetic regulators of ovarian aging and longevity. Relationship between liver and cardiometabolic health in type 1 diabetes. Editorial: Insights in obesity: 2023. Editorial: Pulmonary fibrosis and endocrine factors.